References
- PrinceMBryceRAlbaneseEWimoARibeiroWFerriCPThe global prevalence of dementia: a systematic review and metaanalysisAlzheimers Dement2013916375.e223305823
- ViñaJLloretAWhy women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-beta peptideJ Alzheimers Dis201020suppl 2S527S53320442496
- AndersenKLaunerLJDeweyMEGender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM Incidence Research GroupNeurology19995391992199710599770
- Department of Statistics, Ministry of the Interior, Taiwan [webpage on the Internet]Statistical Yearbook of Interior 2.01 Available from: www.moi.gov.tw/stat/english/index.aspAccessed December 23, 2015
- BurnsAThe burden of Alzheimer’s diseaseInt J Neuropsychopharmacol200037313811343622
- HaberstrohJHampelHPantelJOptimal management of Alzheimer’s disease patients: clinical guidelines and family adviceNeuropsychiatr Dis Treat2010624325320520788
- SmallGDuboisBA review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patchCurr Med Res Opin200723112705271317892635
- CummingsJWinbladBA rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementiaExpert Rev Neurother20077111457146317997695
- FuhJLWangSJDementia in Taiwan: past, present, and futureActa Neurol Taiwan200817315316118975520
- KurzAFarlowMLefèvreGPharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a reviewInt J Clin Pract200963579980519392927
- BlesaRBallardCOrgogozoJMLaneRThomasSKCaregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer diseaseNeurology2007694 suppl 1S23S2817646620
- WinbladBKawataAKBeusterienKMCaregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s diseaseInt J Geriatr Psychiatry200722548549117407176
- PaiMCArefHBassilNReal-world evaluation of compliance and preference in Alzheimer’s disease treatmentClin Interv Aging2015101779178826622172
- Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human useMed Etika Bioet200291–2121916276663
- EpsteinMInternational Society of PharmacoepidemiologyGuidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiol Drug Saf200514858959515918159
- von ElmEAltmanDGEggerMSTROBE InitiativeThe strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesLancet200737095961453145718064739
- WinbladBCummingsJAndreasenNA six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsuleInt J Geriatr Psychiatry200722545646717380489
- AbetzLRofailDMertzanisPAlzheimer’s disease treatment: assessing caregiver preferences for mode of treatment deliveryAdv Ther200926662764419495575
- GauthierSRobillardACohenSEMBRACE investigatorsReal-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE studyCurr Med Res Opin2013298989100023647369
- BernabeiRRossiniPMDi CioccioLCompliance and caregiver satisfaction in Alzheimer’s disease: results from the AXEPT StudyDement Geriatr Cogn Dis Extra20122141843223139687
- Cruz JentoftAJHernándezBManejo terapéutico con rivastigmina en pacientes con enfermedad de Alzheimer de leve a moderadamente grave en condiciones de práctica clínica habitual. Estudio ENTERPRISE [Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study]Neurologia2014291110 Spanish23582372
- BoadaMArranzFJTransdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer’s disease treated with rivastigmineDement Geriatr Cogn Disord2013351–2233323306147
- WinbladBGrossbergGFrölichLIDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer diseaseNeurology2007694 suppl 1S14S2217646619
- AdlerGMuellerBArticusKThe transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditionsInt J Clin Pract201468446547024588972
- BirksJSGrimley EvansJRivastigmine for Alzheimer’s diseaseCochrane Database Syst Rev20154CD00119125858345